[ad_1]
The Brazilian Association of Vaccine Clinics (ABCVAC) reported that it is negotiating with the Bharat Biotech laboratory of India to acquire five million doses of vaccines against Covid-19. The Indian vaccine is called Covaxin.
Read also
The government bans the export of syringes and needles
Brazil registers 293 deaths from Covid-19 in 24 hours; the total is 196,018
Bolsonaro’s vetoes of LDO do not affect vaccine purchases, says government
The expectation of the sector is that the doses will be available in the national market already in March 2021, in an optimistic scenario.
The president of ABCVAC, Geraldo Barbosa, reported that a memorandum of intent has already been signed between the association and the laboratory, in which interest has been expressed in the purchase of vaccines.
This Monday (4), representatives of the association of private clinics will travel to India, where they will visit the laboratory, to learn about the production capacity and continue with the purchase negotiations.
The Indian company has already carried out procedures with Anvisa for the continuous presentation of vaccine results, a necessary step for registration in Brazil.
The Covaxin vaccine, developed by the Indian company Bharat Biotech, obtained, this Saturday (2), a recommendation for its emergency use in India by the country’s health authorities.
The vaccine, administered in two doses with an interval of two weeks between them, induced a neutralizing antibody, eliciting an immune response and producing effective results in all control groups, without serious adverse events related to the vaccine.
In the last phase before launch for emergency use, it was applied to 26,000 volunteers at 22 locations in India.
Bharat Biotech commits to supply 100 million doses to the Indian government, out of the 300 million doses it has in production capacity.
The factory says it already has 10 million doses ready for use in an emergency.
ABCVAC president Geraldo Barbosa could not specify how much the dose should cost in the Brazilian private network.
The technology used in this vaccine allows storage at temperatures between 2 ° C and 8 ° C. The projection is that its validity against Covid-19 will be 24 months.
ABCVAC has 200 associates who, according to the entity, represent 70% of the national private market.
(Posted by Sinara Peixoto)
